Literature DB >> 25762481

The Impact of Surgical Margin Status on Long-Term Outcome After Resection for Intrahepatic Cholangiocarcinoma.

Gaya Spolverato1, Mohammad Y Yakoob1, Yuhree Kim1, Sorin Alexandrescu2, Hugo P Marques3, Jorge Lamelas3, Luca Aldrighetti4, T Clark Gamblin5, Shishir K Maithel6, Carlo Pulitano7, Todd W Bauer8, Feng Shen9, George A Poultsides10, J Wallis Marsh11, Timothy M Pawlik12,13.   

Abstract

BACKGROUND: The influence of margin status on long-term outcome of patients undergoing liver resection for intrahepatic cholangiocarcinoma (ICC) remains controversial. We sought to study the impact of surgical tumor margin status on recurrence-free survival (RFS) and overall survival (OS) of patients undergoing resection for ICC.
METHODS: From a multi-institutional database, 583 patients who underwent hepatic resection for ICC were identified. Demographics data, operative details, pathologic margin status, and long-term outcomes were collected and analyzed.
RESULTS: Margin status was positive (R1) in 95 (17.8 %) patients; among patients who underwent an R0 resection (80.9 %), margin width was negative by 1-4 mm in 166 (31.0 %) patients, 5-9 mm in 100 (18.7 %) patients, and ≥1 cm in 174 (32.5 %) patients. Overall, 379 (65.0 %) patients had a recurrence: 61.5 % intrahepatic, 13.5 % extrahepatic, and 25.0 % both intra- and extrahepatic. Median and 5-year RFS and OS was 10.0 months and 9.2 %, and 26.4 months and 23.0 %, respectively. Patients who had an R1 resection had a higher risk of recurrence (hazard ratio [HR] 1.61, 95 % CI 1.15-2.27; p = 0.01) and shorter OS (HR 1.54, 95 % CI 1.12-2.11). Among patients with an R0 resection, margin width was also associated with RFS (1-4 mm: HR 1.32, 95 % CI 0.98-1.78 vs. 5-9 mm: HR 1.21, 95 % CI 0.89-1.66) and OS (1-4 mm: HR 1.95, 95 % CI 0.45-2.63 vs. 5-9 mm: HR 1.21, 95 % CI 0.88-1.68) (referent ≥1 cm; both p ≤ 0.002). Margin status and width remain independently associated with RFS and OS on multivariable analyses.
CONCLUSIONS: For patients undergoing resection of ICC, R1 margin status was associated with an inferior long-term outcome. Moreover, there was an incremental worsening RFS and OS as margin width decreased.

Entities:  

Mesh:

Year:  2015        PMID: 25762481     DOI: 10.1245/s10434-015-4472-9

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  31 in total

Review 1.  Surgical options for intrahepatic cholangiocarcinoma.

Authors:  Kui Wang; Han Zhang; Yong Xia; Jian Liu; Feng Shen
Journal:  Hepatobiliary Surg Nutr       Date:  2017-04       Impact factor: 7.293

2.  Defining Long-Term Survivors Following Resection of Intrahepatic Cholangiocarcinoma.

Authors:  Fabio Bagante; Gaya Spolverato; Matthew Weiss; Sorin Alexandrescu; Hugo P Marques; Luca Aldrighetti; Shishir K Maithel; Carlo Pulitano; Todd W Bauer; Feng Shen; George A Poultsides; Oliver Soubrane; Guillaume Martel; B Groot Koerkamp; Alfredo Guglielmi; Endo Itaru; Timothy M Pawlik
Journal:  J Gastrointest Surg       Date:  2017-08-24       Impact factor: 3.452

3.  Can laparoscopic liver resection provide a favorable option for patients with large or multiple intrahepatic cholangiocarcinomas?

Authors:  Fangqiang Wei; Chen Lu; Liuxin Cai; Hong Yu; Xiao Liang; Xiujun Cai
Journal:  Surg Endosc       Date:  2016-12-28       Impact factor: 4.584

4.  Perioperative and Long-Term Outcome for Intrahepatic Cholangiocarcinoma: Impact of Major Versus Minor Hepatectomy.

Authors:  Xu-Feng Zhang; Fabio Bagante; Jeffery Chakedis; Dimitrios Moris; Eliza W Beal; Matthew Weiss; Irinel Popescu; Hugo P Marques; Luca Aldrighetti; Shishir K Maithel; Carlo Pulitano; Todd W Bauer; Feng Shen; George A Poultsides; Oliver Soubrane; Guillaume Martel; B Groot Koerkamp; Alfredo Guglielmi; Endo Itaru; Timothy M Pawlik
Journal:  J Gastrointest Surg       Date:  2017-07-25       Impact factor: 3.452

5.  Yttrium-90 glass microspheres radioembolization (RE) for biliary tract cancer: a large single-center experience.

Authors:  Héloïse Bourien; Xavier Palard; Yan Rolland; Fanny Le Du; Luc Beuzit; Thomas Uguen; Samuel Le Sourd; Marc Pracht; Vincent Manceau; Astrid Lièvre; Karim Boudjema; Etienne Garin; Julien Edeline
Journal:  Eur J Nucl Med Mol Imaging       Date:  2018-10-29       Impact factor: 9.236

6.  The Landmark Series: Intrahepatic Cholangiocarcinoma.

Authors:  Jordan M Cloyd; Aslam Ejaz; Timothy M Pawlik
Journal:  Ann Surg Oncol       Date:  2020-05-17       Impact factor: 5.344

Review 7.  Resection for intrahepatic cholangiocellular cancer: new advances.

Authors:  Daniel R Waisberg; Rafael S Pinheiro; Lucas S Nacif; Vinicius Rocha-Santos; Rodrigo B Martino; Rubens M Arantes; Liliana Ducatti; Quirino Lai; Wellington Andraus; Luiz C D'Albuquerque
Journal:  Transl Gastroenterol Hepatol       Date:  2018-09-12

8.  Surgical management of biliary malignancy.

Authors:  T Peter Kingham; Victoria G Aveson; Alice C Wei; Jason A Castellanos; Peter J Allen; Daniel P Nussbaum; Yinin Hu; Michael I D'Angelica
Journal:  Curr Probl Surg       Date:  2020-06-30       Impact factor: 1.909

9.  Neoadjuvant Chemotherapy for Intrahepatic Cholangiocarcinoma: A Propensity Score Survival Analysis Supporting Use in Patients with High-Risk Disease.

Authors:  Ovie Utuama; Jennifer B Permuth; Getachew Dagne; Aurora Sanchez-Anguiano; Amy Alman; Ambuj Kumar; Jason Denbo; Richard Kim; Jason B Fleming; Daniel A Anaya
Journal:  Ann Surg Oncol       Date:  2021-01-07       Impact factor: 5.344

Review 10.  Management of Intrahepatic Cholangiocarcinoma.

Authors:  Sudha Kodali; Akshay Shetty; Soumya Shekhar; David W Victor; Rafik M Ghobrial
Journal:  J Clin Med       Date:  2021-05-27       Impact factor: 4.241

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.